NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 11 04:00PM ET
3.59
Dollar change
+0.04
Percentage change
1.12
%
Index- P/E- EPS (ttm)-1.93 Insider Own0.28% Shs Outstand36.87M Perf Week-3.23%
Market Cap132.36M Forward P/E- EPS next Y-1.93 Insider Trans0.00% Shs Float36.77M Perf Month0.84%
Enterprise Value-13.18M PEG- EPS next Q-0.50 Inst Own9.72% Short Float0.09% Perf Quarter-3.50%
Income-67.06M P/S52.95 EPS this Y-5.08% Inst Trans1.79% Short Ratio3.13 Perf Half Y-32.90%
Sales2.50M P/B0.91 EPS next Y3.12% ROA-36.69% Short Interest0.03M Perf YTD-24.39%
Book/sh3.93 P/C0.89 EPS next 5Y-5.62% ROE-40.40% 52W High12.22 -70.62% Perf Year-28.06%
Cash/sh4.01 P/FCF- EPS past 3/5Y7.12% -1.12% ROIC-45.96% 52W Low3.36 6.85% Perf 3Y-85.06%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-19.13% -22.75% Gross Margin- Volatility1.78% 4.03% Perf 5Y-
Dividend TTM- EV/Sales-5.27 EPS Y/Y TTM4.11% Oper. Margin-2771.89% ATR (14)0.17 Perf 10Y-
Dividend Ex-Date- Quick Ratio15.28 Sales Y/Y TTM-67.23% Profit Margin-2681.77% RSI (14)44.70 Recom1.33
Dividend Gr. 3/5Y- - Current Ratio15.28 EPS Q/Q-28.37% SMA20-3.59% Beta1.10 Target Price10.37
Payout- Debt/Eq0.02 Sales Q/Q-100.00% SMA50-6.68% Rel Volume0.05 Prev Close3.55
Employees174 LT Debt/Eq0.01 EarningsMay 15 AMC SMA200-24.66% Avg Volume10.79K Price3.59
IPOJun 16, 2021 Option/ShortNo / Yes EPS/Sales Surpr.-28.60% - Trades Volume497 Change1.12%
Date Action Analyst Rating Change Price Target Change
Aug-30-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-29-22Downgrade SVB Leerink Outperform → Mkt Perform $30 → $8
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Jun-22-25 04:00PM
Jun-11-25 04:00PM
Jun-10-25 01:00AM
May-19-25 01:00AM
May-15-25 04:00PM
04:00PM Loading…
Apr-25-25 04:00PM
Apr-16-25 12:00PM
Apr-03-25 09:55AM
Mar-25-25 04:00PM
12:00PM
Mar-06-25 04:00PM
Feb-28-25 01:00AM
Jan-12-25 01:00PM
01:00PM
Dec-17-24 04:00PM
12:00PM Loading…
Dec-08-24 12:00PM
Nov-07-24 04:00PM
Nov-05-24 04:00PM
Oct-31-24 04:00PM
Oct-25-24 01:00AM
Oct-23-24 09:29AM
Oct-22-24 01:00AM
01:00AM
Oct-04-24 01:00AM
Sep-27-24 01:00AM
Aug-26-24 04:00PM
Jul-14-24 12:16PM
Jun-24-24 07:16AM
Jun-20-24 07:28AM
Jun-17-24 01:00AM
07:30AM Loading…
Jun-14-24 07:30AM
01:00AM
Jun-12-24 07:46AM
Jun-11-24 01:00AM
Jun-01-24 08:00AM
May-16-24 04:00PM
Apr-29-24 11:00AM
Apr-19-24 11:12AM
Apr-17-24 11:12AM
Mar-26-24 09:26AM
Mar-14-24 04:00PM
Mar-01-24 04:00PM
Jan-07-24 04:00PM
Jan-05-24 04:00PM
Dec-14-23 01:00AM
Dec-10-23 12:00PM
Nov-14-23 01:00AM
Nov-03-23 12:00PM
Nov-02-23 02:00AM
Nov-01-23 02:00AM
Oct-26-23 04:00PM
Sep-13-23 01:00AM
Aug-24-23 04:00PM
Jul-13-23 08:06AM
Jun-27-23 01:00AM
Jun-19-23 12:00PM
Jun-02-23 08:59AM
May-25-23 05:01PM
May-16-23 04:00PM
May-13-23 02:00AM
May-11-23 04:00PM
Apr-18-23 01:44AM
Apr-14-23 01:00AM
Apr-04-23 11:44AM
Mar-13-23 09:30AM
12:22AM
Mar-11-23 02:14AM
Mar-09-23 04:00PM
Mar-02-23 04:00PM
Feb-28-23 01:15AM
Feb-10-23 01:00AM
Jan-16-23 01:00AM
Jan-12-23 06:18AM
Jan-08-23 03:00PM
Dec-30-22 01:00AM
Dec-12-22 07:00PM
Dec-01-22 11:46PM
Nov-10-22 01:00AM
Nov-04-22 09:39AM
Nov-03-22 12:30PM
Nov-02-22 12:30PM
Oct-27-22 04:00PM
04:00PM
Aug-25-22 04:30PM
Aug-18-22 01:00AM
Jul-21-22 11:30AM
Jun-10-22 01:00AM
May-12-22 04:05PM
May-11-22 01:00AM
May-03-22 12:00PM
Apr-27-22 08:02AM
06:01AM
05:59AM
Apr-26-22 04:05PM
02:00PM
Apr-23-22 01:00AM
Apr-13-22 12:00PM
09:00AM
Mar-24-22 02:00AM
Mar-17-22 01:00AM
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.